Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma(MM) | withdrawn | Phase 4 | 0 | DFINE Inc.INDUSTRY | 0 | Jan 20, 2017 | clinicaltrials |
| NCT01237249 |
| completed |
| Phase 2 |
| 250 |
| PETHEMA FoundationOTHER |
| 1 |
| Jan 18, 2017 |
| clinicaltrials |
| NCT02452099 | Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.(DMSOconc3) | completed | N/A | 150 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01947309 | Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | terminated | — | 176 | CelgeneINDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00405756 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | completed | Phase 3 | 459 | Celgene CorporationINDUSTRY | 22 | Jan 11, 2017 | clinicaltrials |
| NCT00477035 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | completed | Phase 1 | 22 | Sally AraiOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00099047 | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT02997813 | Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies(MOZOBIL) | completed | — | 112 | Intergroupe Francophone du MyelomeNETWORK | 1 | Dec 20, 2016 | clinicaltrials |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant(CARAMEL 2) | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT02981199 | Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients | unknown | N/A | 80 | Chen WenmingOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00040937 | S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00306735 | Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01880762 | Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions | completed | — | 44 | NYU Langone HealthOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00091624 | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | completed | Phase 1 | 77 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma(PANORAMA-5) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 8, 2016 | clinicaltrials |
| NCT01122875 | A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01432353 | A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 39 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01804140 | A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) | completed | — | 662 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02916420 | Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 73 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02011113 | Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT02451592 | Fungemia in Hematologic Malignancies | completed | — | 300 | Sorveglianza Epidemiologica Infezioni Fungine Emopatie MaligneOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT02471820 | Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients(RAD) | completed | Phase 2 | 45 | Meletios A. DimopoulosOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00779922 | Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function | completed | Phase 2 | 39 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00900263 | S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma | completed | — | 375 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 7, 2016 | clinicaltrials |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 12 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | terminated | N/A | 27 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT01580371 | Safety and Pharmacokinetic Profile of CKD-581(CKD-581) | completed | Phase 1 | 39 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00700531 | European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy(EuLITE) | completed | N/A | 90 | University Hospital BirminghamOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT02917239 | Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16) | completed | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Oct 4, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01718899 | Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma | completed | Phase 1 | 22 | OncoPep, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT02116569 | A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Sep 26, 2016 | clinicaltrials |
| NCT00580372 | UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma | completed | Phase 2 | 231 | University of ArkansasOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | terminated | Phase 2 | 58 | Henrik GregersenOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00800839 | Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02230917 | A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | Rebecca SilbermannOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00047788 | Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 24, 2016 | clinicaltrials |
| NCT01362972 | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor | completed | — | 7,801 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 24, 2016 | clinicaltrials |
| NCT01701076 | Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma(BRd) | completed | Phase 2 | 50 | Cantonal Hospital of St. GallenOTHER | 1 | Aug 24, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2017source: clinicaltrials